Moderna and Merck Announce Positive Phase 3 Trial Results for Personalized Cancer Vaccine
On August 19, 2026, Moderna and Merck announced that their personalized melanoma vaccine intismeran, combined with Keytruda, met its primary endpoints in a late-stage clinical trial involving 1,137 patients. The treatment reduced the risk of cancer recurrence or spread compared to Keytruda alone. This marks the first positive Phase 3 result for an mRNA-based cancer vaccine and has been described as clinically meaningful by Merck's Jane Healy. Both companies' stock prices increased following the announcement. Full data will be presented at a medical conference alongside discussions on regulatory filings. Additional trials are underway in other cancers, including lung, bladder, kidney, pancreatic, and stomach cancers. The success of this trial validates Moderna’s mRNA platform beyond infectious diseases and offers Merck an extended competitive edge for Keytruda as its patent nears expiration. However, the treatment is still unapproved and faces challenges related to manufacturing logistics and infrastructure requirements that could limit widespread adoption post-approval.
Topics: cancer_vaccine Keytruda mRNA_technology personalized_medicine